Cadrenal Therapeutics, INC Form 4 insider transactions

James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc., reports the acquisition of stock options.

A director of Cadrenal Therapeutics, Inc. acquired 20,000 stock options on January 23, 2025.

Director Glynn Wilson of Cadrenal Therapeutics, Inc. acquired 20,000 stock options on January 23, 2025, which vest monthly over 12 months starting February 1, 2025.

A director of Cadrenal Therapeutics, Steven Zelenkofske, has acquired 20,000 stock options, vesting monthly over 12 months starting February 1, 2025.

Cadrenal Therapeutics' Chief Operating Officer, Jeffrey Scott Cole, was granted 25,000 stock options on January 23, 2025.

Cadrenal Therapeutics' Chief Financial Officer, Matthew Szot, was granted 50,000 stock options on January 23, 2025.

Cadrenal Therapeutics CEO and Chairman, Quang X. Pham, was granted 65,000 stock options on January 23, 2025.

Robert Lisicki, a director at Cadrenal Therapeutics, acquired 20,000 stock options on January 23, 2025.

CEO Quang Pham of Cadrenal Therapeutics donates 50,000 shares of common stock to a non-profit organization on April 10, 2024.

Jeffrey Scott Cole, Chief Operating Officer of Cadrenal Therapeutics, Inc., acquired options to purchase 150,000 shares of common stock on April 2, 2024.